Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01016834 · ClinicalTrials.gov registry record · Phase 4

Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine

A Phase 4 study, sponsored by Zogenix.

Completed
Registry status
Phase 4
Development phase
246
Enrollment target

NCT01016834 is a Phase 4 study that has completed, run by Zogenix. The registered enrollment target is 246 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01016834, a Phase 4 study, has completed, sponsored by Zogenix.

COMPLETED
Registry status
Phase 4
Development phase
246 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

Interventions

  • DRUG Sumatriptan
  • DEVICE Sumavel DosePro

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2009-11-30
Est. Completion 2010-04-30
Phase Phase 4

Sponsor

Zogenix

9 total trials

What the Registry Record Tells You About NCT01016834

The ClinicalTrials.gov registry entry for NCT01016834 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zogenix, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Sumatriptan is the first listed.

NCT01016834 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01016834 about?

NCT01016834 is a clinical study titled "Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine". The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.

What is the current status of trial NCT01016834?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 246 participants. The study started on 2009-11-30. Estimated completion is 2010-04-30.

What interventions are being tested in trial NCT01016834?

The interventions under investigation include: Sumatriptan (DRUG), Sumavel DosePro (DEVICE).

Who is sponsoring clinical trial NCT01016834?

This trial is sponsored by Zogenix, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.